Division of Hematology and Oncology, University of Cincinnati Medical Center., Cincinnati, OH
Rafiullah Khan , Inas Abuali , Eric J. Vick , Luke Smart , Changchun Xie , Mahmoud Charif
Background: TNBC is a heterogeneous sub-type of breast cancer characterized by younger age of onset, more aggressive course, and higher incidence among African Americans who also experience disparities in access to health care including health insurance coverage and cancer screening. Methods: We performed a retrospective analysis of the NCDB to study the impact of race and insurance status on the stage at diagnosis and overall survival of people with TNBC. Chi-square tests analysis was used for univariate analysis. Cox models were used to test for survival differences between race and insurance status adjusted for other covariates such as age at diagnosis, gender. Results: Among 1,148,016 people with TNBC registered in the NCDB from 2010 to 2016, 87.7% were identified as white and 12.3% were identified as black. The majority (99%) were female. Mean age at diagnosis was 62.0 years for females and 65.9 years for males. Among white patients, 1.8% were uninsured while 3.6% of black patients were uninsured. Advanced stage at diagnosis was less common among white people (9.4%, Stage 3; 4.9%, Stage 4) than black people (13.3%, Stage 3; 7.6%, Stage 4). Uninsured patients had more advanced disease at time of diagnosis (16.2%, Stage 3; 14.1%, Stage 4) than insured patients (9.8%, Stage 3; 5.0%, Stage 4). Overall survival after adjustment for age at diagnosis, gender and insurance status was greater for white patients compared to black patients (harm ratio 0.60). Overall survival after adjustment for age at diagnosis, gender and race was lower for uninsured patients than insured patients (harm ratio 2.25). Conclusions: Racial disparities significantly affect TNBC patients, with black women having lower insurance coverage and worse overall survival.
Race | Stage 1 | Stage 2 | Stage 3 | Stage 4 | Total | P-value |
---|---|---|---|---|---|---|
White | 559,953 (55.6%) | 302,690 (30.1%) | 94,855 (9.4%) | 49,133 (4.5%) | 1,006,631 (100%) | |
Black | 61,949 (43.8%) | 49,910 (35.3%) | 18,776 (13.3%) | 10,750 (7.6%) | 141,385 (100%) | |
Total | 621,902 (54.2%) | 352,600 (30.7%) | 113,631 (9.9%) | 59,883 (5.2%) | 1,148,016 (100%) | <0.0001 |
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Abstract Disclosures
2023 ASCO Annual Meeting
First Author: Chirag Patel
2024 ASCO Genitourinary Cancers Symposium
First Author: Helen Gao
2022 ASCO Annual Meeting
First Author: Alexandra Taylor
2023 ASCO Annual Meeting
First Author: Kekoa A. Taparra